Core Insights - Exousia Bio, Inc. is transitioning from LAMY and focuses on exosome-based cancer therapies, emphasizing its commitment to innovation in healthcare [2][5] - Dr. Marvin Hausman, a strategic consultant with over 50 years of experience in drug development, has joined the company, bringing significant expertise to its strategic initiatives [2][4] Company Overview - Exousia Bio, Inc. specializes in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for targeted delivery to tissues and cells [5] - The company’s platform allows for the custom production of exosomes with enhanced genetic functionality, targeting specific cells to address diseases with significant unmet medical needs [5] Strategic Vision - Dr. Hausman aims to leverage exosomes as a future healthcare solution, highlighting their role in cellular communication and potential in treating cancers like glioblastoma and small cell lung cancer [4] - The company is focused on targeting cancer stem cells, which are key drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer [5]
Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
Globenewswire·2025-12-04 13:30